Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (71-80 of 268) with videos related to

Pageof 27
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancersAlexander Drilon, Hirofumi Sugita, Camelia S Sima, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2023
Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With SelpercatinibYonina R Murciano-Goroff, Christina J Falcon, Sabrina T Lin, et al.
NPJ Precision Oncology|August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology|August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Nature Communications|July 12, 2017
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic targetPeter J Cook, Rozario Thomas, Ram Kannan, et al.
Nature Communications|March 14, 2018
Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic targetPeter J Cook, Rozario Thomas, Ram Kannan, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?Andrew J Plodkowski, Alexander Drilon, Darragh F Halpenny, et al.
Pageof 27

Showing results (71-80 of 268) with videos related to

Sort By:
Pageof 27
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancersAlexander Drilon, Hirofumi Sugita, Camelia S Sima, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2023
Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With SelpercatinibYonina R Murciano-Goroff, Christina J Falcon, Sabrina T Lin, et al.
NPJ Precision Oncology|August 8, 2024
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
NPJ Precision Oncology|August 28, 2024
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Nature Communications|July 12, 2017
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic targetPeter J Cook, Rozario Thomas, Ram Kannan, et al.
Nature Communications|March 14, 2018
Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic targetPeter J Cook, Rozario Thomas, Ram Kannan, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersRajat Thawani, Matteo Repetto, Clare Keddy, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with <i>ALK</i>-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?Andrew J Plodkowski, Alexander Drilon, Darragh F Halpenny, et al.
Pageof 27